MedPath

Evaluation of a New Silicone Hydrogel Contact Lens

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: Air Optix Aqua
Device: Test lens
Registration Number
NCT01309880
Lead Sponsor
Bausch & Lomb Incorporated
Brief Summary

The objective of this study is to determine the clinical feasibility and to evaluate the product performance of investigational contact lenses developed by Bausch + Lomb.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
66
Inclusion Criteria
  • Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
  • Be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand.
Exclusion Criteria
  • Have worn gas permeable (GP) contact lenses within last 30 days or polymethylmethacrylate (PMMA) lenses within last 3 months.
  • Any systemic disease affecting ocular health.
  • Using any systemic or topical medications that will affect ocular physiology or lens performance.
  • An active ocular disease, any corneal infiltrative response or are using any ocular medications.
  • Any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.
  • Allergic to any component in the study care products.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Air Optix AquaAir Optix AquaCiba Vision daily wear contact lens
Test LensTest lensInvestigational silicone hydrogel contact lens
Primary Outcome Measures
NameTimeMethod
Visual AcuityDispensing & 1-week follow up

Distance high contrast logMAR lens visual acuity (VA) between the Air Optix Aqua lens and the Test Lens at Dispensing and at 1-Week Follow-up.

Secondary Outcome Measures
NameTimeMethod
Slit Lamp Findings1 week

Measured on a scale of 0-4 where 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe for edema, microcysts, corneal staining, limbal injection, bulbar injection, upper lid tarsal conjunctival abnormalities, corneal neovascularization and corneal infiltrates.

Comfort1 Weeks

At 1-Week Follow-up, participants rated lens comfort on a scale of 0 to 100, with 100 being the most favorable score.

Trial Locations

Locations (1)

Bausch & Lomb, Incorporated

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath